Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
暂无分享,去创建一个
L. Lopetuso | F. Scaldaferri | G. Marasco | G. Mocci | L. Pastorelli | O. Nardone | C. Petruzzellis | On Behalf Of The Italian Association Of Young Gast
[1] M. Toruner,et al. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility , 2022, United European gastroenterology journal.
[2] G. Barbara,et al. Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation , 2022, International journal of molecular sciences.
[3] S. Sestito,et al. Role of inflammation in pediatric irritable bowel syndrome , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[4] A. Moschen,et al. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis , 2021, Scandinavian journal of gastroenterology.
[5] S. Danese,et al. Breaking through the therapeutic ceiling: what will it take? , 2021, Gastroenterology.
[6] A. Amiot,et al. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus , 2021, Digestive and Liver Disease.
[7] G. Barbara,et al. Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier , 2021, Frontiers in Nutrition.
[8] V. Andersen,et al. The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study , 2020, United European gastroenterology journal.
[9] L. Peyrin-Biroulet,et al. Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach , 2020, Expert review of gastroenterology & hepatology.
[10] C. Le Berre,et al. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis , 2020, Expert opinion on biological therapy.
[11] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.
[12] G. Barbara,et al. Nerve fiber overgrowth in patients with symptomatic diverticular disease , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[13] Sha Li,et al. Effectiveness of mesalazine to treat irritable bowel syndrome , 2019, Medicine.
[14] F. Pace,et al. Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry , 2019, United European gastroenterology journal.
[15] F. Manguso,et al. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[16] B. Feagan,et al. Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews. , 2018, Inflammatory bowel diseases.
[17] S. Hajibandeh,et al. Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta‐analysis with trial sequential analysis of randomized controlled trials , 2018, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[18] V. Andersen,et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study , 2018, Gut.
[19] Siddharth Singh,et al. Natural History of Adult Ulcerative Colitis in Population‐based Cohorts: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] G. Barbara,et al. Treatment of Diverticular Disease With Aminosalicylates: The Evidence , 2016, Journal of clinical gastroenterology.
[21] P. Malfertheiner,et al. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials , 2016, Journal of clinical gastroenterology.
[22] P. Brigidi,et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease , 2016, Gut.
[23] G. Marasco,et al. Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon , 2016, Digestive Diseases and Sciences.
[24] F. Bazzoli,et al. Randomised controlled trial of mesalazine in IBS , 2014, Gut.
[25] P. Portincasa,et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double‐blind, randomised, placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.
[26] R. Mueller,et al. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.
[27] V. Annese,et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] J. Gisbert,et al. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. , 2010, Journal of Crohn's & colitis.
[29] W. Sandborn,et al. A comparison of budesonide and mesalamine for active Crohn's disease. , 1999, Gastroenterology.
[30] G. Porro,et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. , 1999, Gastroenterology.
[31] D. Jewell,et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. , 1998, The New England journal of medicine.
[32] D. Jewell,et al. A Comparison of Budesonide and Mesalamine for Active Crohn's Disease , 1998 .
[33] I. Beck,et al. Oral 5-ASA Versus Prednisone in Short Term Treatment of Crohn's Disease: A Multicentre Controlled Trial , 1990 .